Kiora Pharmaceuticals, Inc. · NASDAQ:KPRX
Kiora Pharmaceuticals — Investor Presentation (January 2022)
31 slides from Kiora Pharmaceuticals's investor presentation, Jan 11, 2022
Slide 1: Corporate Overview January 2022
CORPORATE OVERVIEW January 2022
Slide 2: Forward Looking Statements
2 Forward Looking Statements Some of the statements in this press release are “forward - looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 . These “forward - looking” statements include statements relating to, among other things, the
Slide 3: Addressing Unmet Needs in Eye Care
3 Addressing Unmet Needs in Eye Care New Leadership – Renewed Focus ▪ Efficient investment to clinical inflection points Compelling Value Proposition Diversified Portfolio Revolutionary small molecule with the potential to restore vision in patients with inherited or age - related retinal degenerati
Slide 4: Pipeline
4 Therapeutic Category Product Delivery Route Indication Development Stage Pre - clinical Phase 1 Phase 2 Phase 3 Anterior Segment Ocular Surface Disease KIO - 101 Eye Drop Ocular Manifestations of Rheumatoid Arthritis Ocular Wound Healing KIO - 201 Eye Drop PRK Surgical Recovery Posterior Segment I
Slide 5: KIO-301 Small Molecule Photoswitch for Retinal Reanimation
5 KIO - 301 Small Molecule Photoswitch for Retinal Reanimation
Slide 6: Retinitis Pigmentosa (RP) Disease Overview
6 Prevalence ▪ 1:3,000 - 1:5,000 (Orphan Disease) Etiology ▪ 50+ genetically distinct subtypes from 150+ mutations ▪ Inherited disease Clinical Presentation ▪ Night blindness, reduced visual field range and eventual loss of central vision ▪ Visual acuity declines Diagnosis ▪ Retinal exam (black bone
Slide 7: RP – How Retinal Degeneration Occurs
7 RP – How Retinal Degeneration Occurs ▪ Normal human retina has about 120 million rods (black & white, night vision, movement) and 6 million cones (color) ▪ Photoreceptors die (rods first, then cones), unable to activate Bipolar cells and Retinal Ganglion Cells (RGCs) ▪ Bipolar cells and RGCs remai
Slide 8: KIO-301 Turns RGCs ON in the Presence of Light
8 KIO - 301 Turns RGCs “ON” in the Presence of Light Neuron. 92, 100 - 113 (2016) trans cis 1. In RP, photoreceptors are no longer viable and therefore their companion “signal” cells (RGCs) are not capable of being activ ate d or set to “OFF” 2. KIO - 301 preferentially enters these “OFF” RGCs and t
Slide 9: KIO-301: Light Intensity and Wavelength
9 Moonlight 100w Incandescent Light Bulb Cloudy Day Sunlight Light Intensity (photons/cm 2 · sec) KIO - 301: Light Intensity and Wavelength Sci. Rep. 7, 45487 (2017), Banghart, Trauner et al (2008) Wavelength (nm) Light Response Index
Slide 10: KIO-301: Phase 1b Study Design
10 Investigator led safety assessment along and between cohorts KIO - 301 X µg KIO - 301 Y µg KIO - 301 Y µg KIO - 301 Z µg 3 Patients (NLP/LP) Contralateral eye of same pts Single IVT dosing (Y > X) Same schedule of activities 3 Patients (HM) 3 Patients (NLP/LP) Cohort 1 X < Y < Z Day 1 Day 2, 4, 7
Slide 11: KIO-101 Potential 1st in Class Treatment for Ocular Manifestations of RA
11 KIO - 101 Potential 1st in Class Treatment for Ocular Manifestations of Rheumatoid Arthritis (RA)
Slide 12: Ocular Involvement of RA Overview
12 Ocular Involvement of RA Overview Large unmet need ▪ 3.3 million people in United States have RA ▪ >30% of these patients have ocular manifestations (~1.1m) ▪ Ocular signs & symptoms are the most common, non - articular manifestations of RA Patient Journey Rheumatoid Arthritis (RA) is a chronic,
Slide 13: RA Ocular Signs & Symptoms are Mediated by T Cells
13 RA Ocular Signs & Symptoms are Mediated by T Cells KIO - 101 acts upstream to inhibit proliferation of T helper cells (Th1 and Th17) in lymph node and on - site to suppress pro - inflammatory cytokine release Arch Ophthalmol . 2012 Jan;130(1):90 - 100
Slide 14: DHODH Inhibitors: Validated Drug Class for Autoimmune Diseases
14 Company Drug Status * Market / Revenue Sanofi Arava (leflunomide) Aubagio (teriflunomide) On market for RA On market for MS ~$2.5B annual revenue Low selectivity and potency results in off - target side effects ▪ Safety concerns of severe liver injury and other adverse events ▪ Black box added re
Slide 15: KIO-101: Exploratory Phase 1b Ocular Surface Inflammation Trial
15 KIO - 101: Exploratory Phase 1b Ocular Surface Inflammation Trial Enrolled Patients w ith Ocular Surface Inflammation* (N=21, 14/7) Randomization Days 1 - 12 BID Dosing Day 20 Final Follow - up Cohort 4: KIO - 101 (0.15%) Cohort 4: Placebo Enrolled healthy volunteer s (N=24, 8/cohort) Dose Escala
Slide 16: Key Takeaways Safety Analysis
16 Key Takeaways Safety Analysis* – Summary Statistics Table (p values) $orb1-Ѵ Ŋ ƐƏƐ -|Ѵo‰-m7lb7 7ov;v|;v|;7bvv-=;ş‰;ѴѴ |oѴ;u-|;7bm0o|__;-Ѵ|_‹ v†0f;1|v-m7|_ov;‰b|_o1†Ѵ-u bmY-ll-ঞomĺb]_7ov; bm1om1Ѵ†vbˆ;ĺ * Safety Population; ** Zero SAEs reported; *** Zero Ocular SAEs r
Slide 17: Key Finding: Conjunctival Hyperemia
17 Key Finding • Hyperemia was a key inclusion criteria • 100% of subjects on active experienced improvement @ D13 • Hyperemia is an acceptable endpoint as a ‘sign’ for US FDA Conjunctival Hyperemia (sign) p value calculated using Fisher’s Exact Test 0 3
Slide 18: Drug Effect Change in Hyperemia By Day
18 Drug Effect Change In Hyperemia By Day Encouraging to see drug effect increase & decrease. Day 20 is 8 days following last dose.
Slide 19: Top-Line Data: OSDI
19 Top - Line Data: OSDI • Inclusion criteria was OSDI > 22 • OSDI measured @ screen & D11 • Active demonstrated small trend toward significance
Slide 20: KIO-201 Accelerating Ocular Surface Wound Healing
20 KIO - 201 11;Ѵ;u-ঞm]1†Ѵ-u"†u=-1;)o†m7;-Ѵbm]
Slide 21: Ocular Surface Diseases
21 Ocular Surface Diseases American Academy of Ophthalmology ~5 million US patients Refractive surgeries (e.g., PRK) Cataracts Collagen cross - linking 9% Wounds: Surgery ~18 million US patients Episodic/mild Moderate Severe ƒƔ ѷ Epitheliopathies: Dry Eye ~2 million US patients Injuries/abrasions Ch
Slide 22: Refractive Surgery Overview
ƑƑ Refractive Surgery Overview American Academy of Ophthalmology, Ocular Surgery News: April 10, 2019 ▪ PRK is a surgical correction of refractive errors for patients who are not suitable candidates for LASIK due to: > Inadequate corneal thickness > Larger pupil size > Dry eye > Anterior basement me
Slide 23: KIO-201 Cross-linked Hyaluronic Acid
23 KIO - 201 ▪ KIO - 201 is based on a modified form of the natural polymer hyaluronic acid (HA) ▪ HA is a material with a high viscosity that promotes wound healing by enabling enhanced cell migration ▪ 5 clinical trials completed (3 PRK surgical recovery and 2 dry eye) > Approximately 400 eyes hav
Slide 24: Study Design
24 !"|†7‹ ;vb]m ClinicalTrials.gov Identifier: NCT03938883 Enrolled patients undergoing PRK surgery (N=250) Day 0 PRK Surgery Week 2 Post - surgery Follow - up Measure differences in outcomes Screening (n=234) KIO - 201 (QID – Eye Drop) "|-m7-u7 Ŋ o= Ŋ -u;Ő-m7-];om|-1|;mvő Randomize Day 2
Slide 25: KIO-201 Demonstrated Superiority versus BCL
25 Recurrent Erosion ▪ Only 1 (0.9%) study eye in the KIO - 201 group had recurrent erosion ▪ 4 (3.5%) study eyes in the Bandage Contact Lens (BCL) group had recurrent erosion KIO - 201 Demonstrated Superiority versus BCL Percent of Patients with Complete Re - Epithelialization Day 3 (Mean ± SEM) ;
Slide 26: Corporate Overview
Corporate Overview 26 | @KIORA
Slide 27: Executive Team
27 Executive Team Brian M Strem, PhD President & CEO u;m7--mmķ _ ( ŋ !;v;-u1_ Sarah Romano, CPA Chief Financial Officer Stefan Sperl, PhD EVP – CMC & Operations Eric J Daniels, MD, MBA Chief Development Officer Angela Dentiste, MBA VP – Clinical Operations
Slide 28: Board of Directors
28 Board of Directors Stephen From Executive Chairman ub-m"|u;lķ _ u;vb7;m|ş Paul Chaney Lead Independent Director Aron Shapiro Ken Gayron Praveen Tyle David Hollander, MD, MBA
Slide 29: Scientific Advisory Board
29 Scientific Advisory Board -mb;Ѵ †uub;ķ Russel Van Gelder, MD, PhD Charlie Wykoff, MD Victor Perez, MD Francis Mah, MD Paul Karpecki, OD, FAAO Allen Ho, MD, PhD Christine Kay, MD, PhD t¯ãØ›È Y›ã¯Â‚¼ ]]I0d]
Slide 30: Key Expected 2022 Milestones
30 Key Expected 2022 Milestones KIO - 301 ODD KIO - 201 Regulatory Path Clarity* KIO - 301 Ph1b Approval KIO - 301 pIND * - After regulatory clarity from FDA, will seek commercial partnership FPI – First Patient In, ODD – Orphan Drug Designation Ŋ ƒƏƐ _ Ɛ 0 KIO - 101 Ph2 FPI Q1 Q2 Q3 Q4
Slide 31: Contact
om|-1|Ĺ bm=oŠhbou-r_-ul-ĺ1ol
Kiora Pharmaceuticals — Investor Presentation (January 2022) on 6ix